Valink Therapeutics valuation, funding and investors
Valink Therapeutics works in oncology therapeutics research and development, based in London, United Kingdom. Founded in 2021, it has about 30 employees.
- Last round
- Seed · $7.80M · Nov 2023
- Valuation at last round
- $47.7M · implied
- Headcount
- 30 · up
- Grade
- D
- Founded
- 2021
Valink Therapeutics valuation today
VCMC values Valink Therapeutics at $115M today, with a range of $13.8M to $175M and a grade of D. The valuation starts from its last funding round, a seed round in Nov 2023.
Valuation by date (72 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2021 | $10.7M | $3.89M – $29.3M | $11.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2021 | $10.8M | $3.93M – $29.6M | $12.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2021 | $10.9M | $3.96M – $29.9M | $12.1M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2021 | $11.0M | $3.99M – $30.1M | $12.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2021 | $11.1M | $4.03M – $30.4M | $12.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2021 | $11.2M | $4.07M – $30.7M | $12.3M (+10%) | before first round | – | unknown | D | 0% |
| 1 Jul 2021 | $11.3M | $4.10M – $31.0M | $12.4M (+10%) | before first round | – | unknown | D | 0% |
| 1 Aug 2021 | $11.4M | $4.14M – $31.2M | $12.5M (+10%) | before first round | – | unknown | D | 0% |
| 1 Sep 2021 | $11.5M | $4.18M – $31.5M | $12.6M (+10%) | before first round | – | unknown | D | 0% |
| 1 Oct 2021 | $11.6M | $4.22M – $31.8M | $12.7M (+10%) | before first round | – | unknown | D | 0% |
| 1 Nov 2021 | $11.7M | $4.25M – $32.1M | $12.8M (+10%) | before first round | – | unknown | D | 0% |
| 1 Dec 2021 | $11.8M | $4.29M – $32.4M | $12.9M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jan 2022 | $11.9M | $4.33M – $32.7M | $13.0M (+9%) | before first round | – | unknown | D | 0% |
| 1 Feb 2022 | $12.0M | $4.36M – $32.9M | $13.1M (+9%) | before first round | – | unknown | D | 0% |
| 1 Mar 2022 | $12.1M | $4.39M – $33.2M | $13.2M (+9%) | before first round | – | unknown | D | 0% |
| 1 Apr 2022 | $12.2M | $4.43M – $33.4M | $13.3M (+9%) | before first round | – | unknown | D | 0% |
| 1 May 2022 | $12.2M | $4.46M – $33.6M | $13.4M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jun 2022 | $12.3M | $4.49M – $33.9M | $13.5M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jul 2022 | $12.4M | $4.53M – $34.1M | $13.6M (+9%) | before first round | – | unknown | D | 0% |
| 1 Aug 2022 | $12.5M | $4.56M – $34.4M | $13.7M (+9%) | before first round | – | unknown | D | 0% |
| 1 Sep 2022 | $12.6M | $4.59M – $34.7M | $13.8M (+9%) | before first round | – | unknown | D | 0% |
| 1 Oct 2022 | $12.7M | $4.63M – $34.9M | $13.9M (+9%) | before first round | – | unknown | D | 0% |
| 1 Nov 2022 | $12.8M | $4.66M – $35.2M | $14.0M (+9%) | before first round | – | unknown | D | 0% |
| 1 Dec 2022 | $12.9M | $4.70M – $35.4M | $14.1M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jan 2023 | $13.0M | $4.73M – $35.7M | $14.2M (+9%) | before first round | – | unknown | D | 0% |
| 1 Feb 2023 | $13.1M | $4.77M – $36.0M | $14.3M (+9%) | before first round | – | unknown | D | 0% |
| 1 Mar 2023 | $13.2M | $4.80M – $36.2M | $14.4M (+9%) | before first round | – | unknown | D | 0% |
| 1 Apr 2023 | $13.3M | $4.83M – $36.5M | $14.5M (+9%) | before first round | – | unknown | D | 0% |
| 1 May 2023 | $13.4M | $4.87M – $36.7M | $14.6M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jun 2023 | $13.5M | $4.91M – $37.0M | $14.7M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jul 2023 | $13.6M | $4.94M – $37.3M | $14.8M (+9%) | before first round | – | unknown | D | 0% |
| 1 Aug 2023 | $13.7M | $4.98M – $37.6M | $14.8M (+8%) | before first round | – | unknown | D | 0% |
| 1 Sep 2023 | $13.8M | $5.02M – $37.9M | $14.8M (+8%) | before first round | – | unknown | D | 0% |
| 1 Oct 2023 | $13.9M | $5.05M – $38.1M | $14.8M (+7%) | before first round | – | unknown | D | 0% |
| 1 Nov 2023 | $14.0M | $5.09M – $38.4M | $14.8M (+6%) | before first round | – | unknown | D | 0% |
| 17 Nov 2023 | $47.8M | $31.3M – $145M | $95.4M (+100%) | after a round | – | unknown | C | 0% |
| 1 Dec 2023 | $49.1M | $31.3M – $145M | $95.4M (+94%) | after a round | – | unknown | C | 0% |
| 1 Jan 2024 | $52.1M | $31.3M – $145M | $95.4M (+83%) | after a round | – | unknown | C | 0% |
| 1 Feb 2024 | $55.2M | $31.3M – $145M | $95.4M (+73%) | after a round | – | unknown | C | 0% |
| 1 Mar 2024 | $58.3M | $31.3M – $145M | $95.4M (+64%) | after a round | – | unknown | C | 0% |
| 1 Apr 2024 | $61.9M | $31.3M – $145M | $95.4M (+54%) | after a round | 13 | unknown | C | 0% |
| 1 May 2024 | $65.5M | $31.3M – $145M | $95.4M (+46%) | after a round | 13 | unknown | C | 0% |
| 1 Jun 2024 | $69.5M | $31.3M – $145M | $95.4M (+37%) | after a round | 13 | unknown | C | 0% |
| 1 Jul 2024 | $73.5M | $31.3M – $145M | $95.4M (+30%) | after a round | 13 | unknown | C | 0% |
| 1 Aug 2024 | $79.8M | $32.3M – $150M | $98.5M (+23%) | after a round | 15 | up | C | 0% |
| 1 Sep 2024 | $83.8M | $31.9M – $148M | $97.0M (+16%) | after a round | 14 | flat | C | 0% |
| 1 Oct 2024 | $88.8M | $31.9M – $148M | $97.0M (+9%) | after a round | 14 | flat | C | 0% |
| 1 Nov 2024 | $94.3M | $31.9M – $148M | $97.0M (+3%) | after a round | 14 | flat | C | 0% |
| 1 Dec 2024 | $99.9M | $32.3M – $152M | $99.9M (0%) | after a round | 16 | up | C | 0% |
| 1 Jan 2025 | $99.9M | $31.3M – $152M | $99.9M (0%) | after a round | 16 | up | C | 0% |
| 1 Feb 2025 | $99.9M | $30.4M – $152M | $99.9M (0%) | after a round | 16 | up | C | 0% |
| 1 Mar 2025 | $99.9M | $29.6M – $152M | $99.9M (0%) | after a round | 16 | up | C | 0% |
| 1 Apr 2025 | $99.9M | $28.7M – $152M | $99.9M (0%) | after a round | 16 | up | C | 0% |
| 1 May 2025 | $99.9M | $27.9M – $152M | $99.9M (0%) | after a round | 16 | up | C | 0% |
| 1 Jun 2025 | $99.9M | $27.1M – $152M | $99.9M (0%) | after a round | 16 | up | C | 0% |
| 1 Jul 2025 | $99.9M | $26.3M – $152M | $99.9M (0%) | after a round | 16 | up | C | 0% |
| 1 Aug 2025 | $99.9M | $25.5M – $152M | $99.9M (0%) | after a round | 16 | up | C | 0% |
| 1 Sep 2025 | $109M | $37.4M – $166M | $109M (0%) | after a round | 24 | growing | C | 0% |
| 1 Oct 2025 | $109M | $37.5M – $166M | $109M (0%) | after a round | 24 | growing | C | 0% |
| 1 Nov 2025 | $109M | $37.7M – $166M | $109M (0%) | after a round | 24 | growing | C | 0% |
| 1 Dec 2025 | $112M | $34.7M – $171M | $112M (0%) | after a round | 27 | growing | C | 0% |
| 1 Jan 2026 | $113M | $34.8M – $172M | $113M (0%) | after a round | 28 | growing | C | 0% |
| 1 Feb 2026 | $113M | $34.7M – $172M | $113M (0%) | after a round | 28 | growing | C | 0% |
| 1 Mar 2026 | $113M | $34.5M – $172M | $113M (0%) | after a round | 28 | growing | C | 0% |
| 1 Apr 2026 | $113M | $34.4M – $172M | $113M (0%) | after a round | 28 | growing | C | 0% |
| 1 May 2026 | $116M | $35.2M – $177M | $116M (0%) | after a round | 32 | growing | C | 0% |
| 1 Jun 2026 | $116M | $17.2M – $177M | $116M (0%) | after a round | 32 | up | D | 0% |
| 1 Jul 2026 | $116M | $16.4M – $177M | $116M (0%) | after a round | 32 | up | D | 0% |
| 1 Aug 2026 | $116M | $15.7M – $177M | $116M (0%) | after a round | 32 | up | D | 0% |
| 1 Sep 2026 | $116M | $15.1M – $177M | $116M (0%) | after a round | 32 | up | D | 0% |
| 1 Oct 2026 | $115M | $14.2M – $175M | $114M (0%) | after a round | 30 | up | D | 0% |
| 24 Oct 2026 | $115M | $13.8M – $175M | $114M (0%) | after a round | 30 | up | D | 0% |
Key facts about Valink Therapeutics
- Founded
- 2021
- Headquarters
- London, United Kingdom
- Employees
- about 30 +25% in a year
- Total raised
- $7.8M
- Funding rounds
- 1
- Last round
- Seed Nov 2023
Valink Therapeutics was founded in 2021 by Arne Scheu and Irsyad Khairil.
Valink Therapeutics funding history
Valink Therapeutics has 1 funding round on record, from Nov 2023 to Nov 2023, $7.8M in total. None disclosed a valuation.
Seed 16 Nov 2023
Led by RV Invest; with Hoxton Ventures, SynBioVen, Metaplanet, Acequia Capital, Magnet Ventures, Oxonian Ventures, Innovate UK.
Sources: londonlovesbusiness.com, htworld.co.uk, intelligenthealth.tech and 2 more
$7.8M
Valink Therapeutics investors
8 investors have backed Valink Therapeutics; RV Invest led at least one round.
- Acequia Capital
- Hoxton Ventures
- Innovate UK
What Valink Therapeutics does
Valink Therapeutics works in pharmaceutical products, with 10 recorded offerings and customers in healthcare and pharmaceuticals.
Valink Therapeutics Ltd is a biotechnology company engaged in the development of therapeutic solutions for cancer treatment, with a focus on bispecific antibody-drug conjugates (ADCs) and proprietary technologies such as the LiliumX™ platform, which integrates synthetic protein biology, high-throughput functional screening, and artificial intelligence to identify potential drugs. The company is advancing oncology-focused programs targeting various cancer types, including colorectal cancer, non-small cell lung cancer, and solid tumors.
Description from Veridion's company data.
Products and services
- Oncology Therapeutics Research and Development
- Bispecific Antibody-Drug Conjugate Development
- Synthetic Protein Biology Application
- High-Throughput Functional Screening Execution
- AI-Driven Drug Discovery
- Proprietary Platform Utilization for Drug Discovery
- Solid Tumor Therapeutics Development
- Colorectal Cancer Therapeutics Development
- Non-Small Cell Lung Cancer Therapeutics Development
- Biologics Discovery Collaboration
Markets
- Healthcare
- Pharmaceuticals
Technology
- Synthetic Protein Biology
- High-Throughput Functional Screening
- Artificial Intelligence for Drug Identification
- Bispecific Antibody-Drug Conjugates
Business model
- Business-to-Business
- Manufacturing
Industry codes (NAICS)
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match
Questions about Valink Therapeutics
What is Valink Therapeutics worth?
Valuation $115M (range $13.8M to $175M), as of 24 Oct 2026.
Has Valink Therapeutics raised money?
Valink Therapeutics has 1 funding round on record, from Nov 2023 to Nov 2023, $7.8M in total. None disclosed a valuation.
Who has invested in Valink Therapeutics?
RV Invest, Acequia Capital, Hoxton Ventures, Innovate UK, Magnet Ventures and Metaplanet, and 2 more. Lead investors include RV Invest.
How many people work at Valink Therapeutics?
About 30, up 25% over the last year. Headcount grew from 13 in Mar 2024 to 30 in Sep 2026.
What does Valink Therapeutics do?
Valink Therapeutics works in pharmaceutical products, with 10 recorded offerings and customers in healthcare and pharmaceuticals. Its main offerings are oncology therapeutics research and development, bispecific antibody-drug conjugate development and synthetic protein biology application.
When was Valink Therapeutics founded, and where is it based?
Valink Therapeutics was founded in 2021 and is based in London, United Kingdom. It has about 30 employees, up 25% over the last year.